ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

NFX Nuformix Plc

0.058
0.004 (7.41%)
03 Dec 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Nuformix Plc LSE:NFX London Ordinary Share GB00BYW79Y38 ORD 0.05P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.004 7.41% 0.058 0.056 0.06 0.06 0.053 0.06 60,546,540 16:35:10
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 0 -859k -0.0010 -0.60 442.43k

Nuformix PLC Director/PDMR Dealings

05/11/2024 2:25pm

RNS Regulatory News


RNS Number : 0442L
Nuformix PLC
05 November 2024
 

5 November 2024

 

Nuformix plc

 

("Nuformix" or the "Company" or the "Group")

 

Director/PDMR Dealings

 

Nuformix plc (LSE:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces further to the completion of the Placing and Subscription to raise gross proceeds of £300,000, as announced on 20 September 2024, and Admission of the New Ordinary Shares today, further details of the Directors' participation in the Fundarise.

 

Each of the Company's Directors have subscribed for the following New Ordinary Shares at the Issue Price:

 

Name

Position

Ordinary shares subscribed for

% held of enlarged share capital on Admission

Julian Gilbert

Non-Executive Chairman

22,000,000

1.57%

Maddy Kennedy

Non-Executive Director

22,000,000

1.57%

Dan Gooding

Executive Director

12,000,000

3.49%

 

The notifications below, made in accordance with the requirements of the EU Market Abuse Regulation (2014/596/EU) as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 and as modified by or under the European Union (Withdrawal) Act 2018 or other domestic law, provides further detail.

 

Terms used in this announcement shall, unless the context otherwise requires, be as defined in the Prospectus published by the Company on 16 October 2024.

 

Enquiries:

 

Nuformix plc

 

Dr Dan Gooding, Executive Director

 

Via IFC Advisory

 

CMC Markets


Douglas Crippen

+44 (0) 20 3003 8632



IFC Advisory Limited


Tim Metcalfe

Zach Cohen

+44 (0) 20 3934 6630

nuformix@investor-focus.co.uk

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Julian Gilbert

2

Reason for the notification

a)

Position/status

Non-Executive Chairman

b)

Initial notification/ Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Nuformix plc

b)

LEI

2138003XG3H3I2J3BJ24

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of nominal value 0.05 pence

 

GB00BYW79Y38

b)

Nature of the transaction

Purchase of ordinary shares

c)

Price(s) and volume(s)

 

Price(s) Volume(s)

0.05 pence

22,000,000

d)

Aggregated information

- Aggregated volume

- Price

 

22,000,000

£11,000

e)

Date of the transaction

5 November 2024

f)

Place of the transaction

Outside a trading venue

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Maddy Kennedy

2

Reason for the notification

a)

Position/status

Non-Executive Director

b)

Initial notification/ Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Nuformix plc

b)

LEI

2138003XG3H3I2J3BJ24

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of nominal value 0.05 pence

 

GB00BYW79Y38

b)

Nature of the transaction

Purchase of ordinary shares

c)

Price(s) and volume(s)

 

Price(s) Volume(s)

0.05 pence

22,000,000

d)

Aggregated information

- Aggregated volume

- Price

 

22,000,000

£11,000

e)

Date of the transaction

5 November 2024

f)

Place of the transaction

Outside a trading venue

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Dan Gooding

2

Reason for the notification

a)

Position/status

Executive Director

b)

Initial notification/ Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Nuformix plc

b)

LEI

2138003XG3H3I2J3BJ24

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of nominal value 0.05 pence

 

GB00BYW79Y38

b)

Nature of the transaction

Purchase of ordinary shares

c)

Price(s) and volume(s)

 

Price(s) Volume(s)

0.05 pence

12,000,000

d)

Aggregated information

- Aggregated volume

- Price

 

12,000,000

£6,000

e)

Date of the transaction

5 November 2024

f)

Place of the transaction

Outside a trading venue

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHFLFFSLSLEIIS

1 Year Nuformix Chart

1 Year Nuformix Chart

1 Month Nuformix Chart

1 Month Nuformix Chart

Your Recent History

Delayed Upgrade Clock